Filtered By:
Condition: Amyloidosis
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 63 results found since Jan 2013.
Echocardiographic indices of left ventricular function and filling pressure are not related to blood pool activity on pyrophosphate scintigraphy
ConclusionApproximately 8% of patients with a negative PYP SPECT have significant blood pool activity. Measures of cardiac function are not different among those with and without blood pool activity. PYP SPECT should be routinely performed in all patients to avoid false image interpretation.
Source: Journal of Nuclear Cardiology - May 16, 2022 Category: Nuclear Medicine Source Type: research
Clinical features and predictors of atrial fibrillation in patients with light ‐chain or transthyretin cardiac amyloidosis
ConclusionsAtrial fibrillation affects nearly half of all patients with CA. Patients presenting with AF have more severe symptoms and higher burden of comorbidities. ATTR type of amyloidosis is the strongest predictor of AF. Prospective screening for occult AF may be considered in ATTR-CA.
Source: ESC Heart Failure - February 18, 2022 Category: Cardiology Authors: Maria Papathanasiou,
Aiste ‐Monika Jakstaite,
Sara Oubari,
Johannes Siebermair,
Reza Wakili,
Julia Hoffmann,
Alexander Carpinteiro,
Tim Hagenacker,
Andreas Thimm,
Christoph Rischpler,
Lukas Kessler,
Tienush Rassaf,
Peter Luedike Tags: Original Article Source Type: research
Direct Oral Anticoagulants in Cardiac Amyloidosis –Associated Heart Failure and Atrial Fibrillation
Atrial fibrillation (AF) is present in approximately 40% of patients with cardiac amyloidosis.1 AF in the setting of cardiac amyloidosis is associated with a significant risk of stroke and systemic thromboembolism regardless of the patient's CHA ₂DS₂-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex category) score.2 Although current guidelines recommend anticoagulation therapy in all patients with cardiac amyloidosis and AF, data about the comparative effectiveness and safety of vitamin K antagonists (VKAs) ...
Source: The American Journal of Cardiology - November 27, 2021 Category: Cardiology Authors: Amgad Mentias, Paulino Alvarez, Pulkit Chaudhury, Michael Nakhla, Rohit Moudgil, Mohamad Kanj, Mazen Hanna, Milind Y. Desai Source Type: research
Targeted RNA Sequencing of VZV-Infected Brain Vascular Adventitial Fibroblasts Indicates That Amyloid May Be Involved in VZV Vasculopathy
Discussion
Gene expression profiles and pathway enrichment analysis of VZV-infected HBVAFs, as well as phenotypic studies, reveal features of pathologic vascular remodeling (e.g., increased cell migration and changes in the extracellular matrix) that can contribute to cerebrovascular disease. Furthermore, the discovery of amyloid-associated transcriptional pathways and intracellular amyloid deposition in HBVAFs raise the possibility that VZV vasculopathy is an amyloid disease. Amyloid deposition may contribute to cell death and loss of vascular wall integrity, as well as potentiate chronic inflammation in VZV vasculopathy,...
Source: Neurology Neuroimmunology and Neuroinflammation - November 10, 2021 Category: Neurology Authors: Bubak, A. N., Como, C. N., Hassell, J. E., Mescher, T., Frietze, S. E., Niemeyer, C. S., Cohrs, R. J., Nagel, M. A. Tags: Vasculitis, Viral infections, All Cerebrovascular disease/Stroke, All Cognitive Disorders/Dementia, Gene expression studies Article Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Trends, Associations, and Impact of Atrial Fibrillation in Patients With Light-chain Cardiac Amyloidosis
In this study, we investigated the temporal trends in the prevalence and prognostic implication of atrial fibrillation (AF) in patient with light-chain cardiac amyloidosis (AL-CA).
Methods:
We identified 3030 patients with AL-CA from the 2015 to 2017 National Inpatient Sample, of which 1577 (52%) had AF. We used trend analysis to assess the temporal trends in the prevalence of AF by subtype from 2015 to 2017. We compared inhospital mortality, acute on chronic heart failure, stroke, length of stay (LOS), and total cost in patients with to those without AF, stratified by subtype of AF.
Results:
The prevalence o...
Source: Critical Pathways in Cardiology - August 28, 2021 Category: Cardiology Tags: Original Study Source Type: research
28675 A case of systemic amyloidosis diagnosed by dermatologic consult
A 49-year-old male with PMH of hypertension and diabetes was admitted to the neurology ICU following thrombolytic therapy for left MCA occlusive thrombus. Dermatology was consulted for desquamation of the lower lip, lateral tongue, and bruising of the eyelid and cheeks. Patient originally presented to outside hospital with bilateral lower extremity swelling and shortness of breath. BNP and troponins were elevated, and ACS protocol was initiated. He had stroke-like symptoms while at the outside facility and CT showed MCA occlusive thrombus.
Source: Journal of the American Academy of Dermatology - August 8, 2021 Category: Dermatology Authors: Alison Huber, Dr. Emily Smith Source Type: research
Cerebral blood flow and cerebrovascular reactivity are preserved in a mouse model of cerebral microvascular amyloidosis
Impaired cerebrovascular function is an early biomarker for cerebral amyloid angiopathy (CAA), a neurovascular disease characterized by amyloid- β accumulation in the cerebral vasculature, leading to stroke and dementia. The transgenic Swedish Dutch Iowa (Tg-SwDI) mouse model develops cerebral microvascular amyloid-β deposits, but whether this leads to similar functional impairments is incompletely understood. We assessed cerebrovascular f unction longitudinally in Tg-SwDI mice with arterial spin labeling (ASL)-magnetic resonance imaging (MRI) and laser Doppler flowmetry (LDF) over the course of amyloid-β deposition. Un...
Source: eLife - February 12, 2021 Category: Biomedical Science Tags: Neuroscience Source Type: research
Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Myocardial Contraction Fraction in Outcomes in Transthyretin Amyloidosis
Myocardial contraction fraction (MCF), the ratio of stroke volume to myocardial volume, is a novel index of myocardial function that is a volumetric measure of myocardial shortening, highly correlated with global longitudinal strain. Previous studies have demonstrated that MCF can distinguish between physiological and pathological causes of hypertrophy and is superior to ejection fraction (EF) in predicting mortality in transthyretin cardiac amyloidosis (ATTR-CA). The association of MCF on major adverse cardiac events (MACE) in ATTR-CA while on disease modifying therapy has not yet been defined.
Source: Journal of Cardiac Failure - September 30, 2020 Category: Cardiology Authors: Sunil E. Saith, Danilo Gamino, Sergio Teryua, Jeffeny De Los Santos, Samantha Guadalupe, Margaret Cuomo, Carlos Rodriguez, Stephen Helmke, Hannah Rosenblum, Jan M. Griffin, Mathew S. Maurer Tags: 090 Source Type: research
Transthyretin cardiac amyloidosis.
Authors: Eicher JC, Audia S, Damy T
Abstract
Transthyretin (TTR) cardiac amyloidosis results from the dissociation of the tetrameric, liver-synthetized transport protein, either because of a mutation (hereditary CA), or spontaneously due to ageing (wild type CA). Monomers self-associate into amyloid fibrils within the myocardium, causing heart failure, arrhythmias and conduction defects. This overlooked disease must be recognized in case of unexplained increased thickness of the myocardium, particularly in subjects of African descent, in patients with heart failure and preserved ejection fraction, and in those with...
Source: Revue de Medecine Interne - August 23, 2020 Category: Internal Medicine Tags: Rev Med Interne Source Type: research
Spectrum of transthyretin gene mutations and clinical characteristics of Polish patients with cardiac transthyretin amyloidosis.
CONCLUSIONS: According to available research, this is the first time types of TTR mutations and clinical characteristics of Polish patients with cardiac hereditary ATTR have been reported. Previous literature data about Polish background in families with p.Phe53Leu mutation and the present results, suggest that this TTR mutation might be endemic in the Polish population.
PMID: 32789836 [PubMed - as supplied by publisher]
Source: Cardiology Journal - August 12, 2020 Category: Cardiology Authors: Gawor M, Holcman K, Franaszczyk M, Lipowska M, Michałek P, Teresińska A, Bilińska ZT, Rubiś P, Kostkiewicz M, Szot W, Podolec P, Grzybowski J Tags: Cardiol J Source Type: research
Cardiac involvement, morbidity and mortality in hereditary transthyretin amyloidosis because of p.Glu89Gln mutation
Conclusion
Cardiac involvement is common and has significant prognostic implications in the evaluated patients with p.Glu89Gln mutation. Heart failure and rhythm disturbances are the main causes of death. An earlier identification of the disease is crucial to improve prognosis.
Source: Journal of Cardiovascular Medicine - August 3, 2020 Category: Cardiology Tags: Research articles: Heart failure Source Type: research
Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis.
CONCLUSIONS: ACEi/ARB and MRA can be safely used in CA, provided that no contraindications are present, treatment is started at a low dose and slowly up-titrated, and patients are monitored quite closely. Beta-blocker therapy is less tolerated in patients with AL amyloidosis and/or worse haemodynamic function.
PMID: 32475765 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - May 27, 2020 Category: Internal Medicine Authors: Aimo A, Vergaro G, Castiglione V, Rapezzi C, Emdin M Tags: Eur J Intern Med Source Type: research
